Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma

Keywords

Serous carcinoma, Serous fluid, Comparative genomic hybridization, Carcinoma, Pathology

References

• Fbxw7 in cell cycle exit and stem cell maintenance: Insight from gene-targeted miceLuis Terol Miller — 2008
• Integrated Genomic Characterization of Endometrial CarcinomaGad Getz, Stacey Gabriel, Kristian Cibulskis — 2013
• Deregulated cyclin E induces chromosome instabilityCharles Spruck, Kwang‐Ai Won, Steven I. Reed — 1999
• Cyclin E in human cancersR. Donnellan, Runjan Chetty — 1999
• Shortened Telomeres in Serous Tubal Intraepithelial Carcinoma: An Early Event in Ovarian High-grade Serous CarcinogenesisElisabetta Kuhn, Alan K. Meeker, Tian‐Li Wang — 2010
• Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinomaElisabetta Kuhn, Alan K. Meeker, Kala Visvanathan — 2011
• The Oncogenic Activity of Cyclin E Is Not Confined to Cdk2 Activation Alone but Relies on Several Other, Distinct Functions of the Protein*Christoph Geisen, Tarik Möröy — 2002
• The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysisElisabetta Kuhn, A. Ayhan, Ie‐Ming Shih — 2013
• Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinomaSiming Zhao, Murim Choi, John D. Overton — 2013
• p53 gain-of-function cancer mutants induce genetic instability by inactivating ATMHoseok Song, Monica Hollstein, Yang Xu — 2007
• Guilt by association? p53 and the development of aneuploidy in cancer.Anette Duensing, Stefan Duensing — 2005
• Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genesMatthieu Le Gallo, Andrea O’Hara, Meghan L. Rudd — 2012
• Functional characterization of the 19q12 amplicon in grade III breast cancersRachael Natrajan, Alan Mackay, Paul M Wilkerson — 2012
• A mouse model for cyclin E-dependent genetic instability and tumorigenesis.Keith R. Loeb, Heather Kostner, Eduardo Firpo — 2005
• Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancerNaomi Nakayama, Kentaro Nakayama, Shamima Yeasmin — 2010
• Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian CancerDariush Etemadmoghadam, Joshy George, Prue A. Cowin — 2010
• TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma—evidence supporting the clonal relationship of the two lesionsElisabetta Kuhn, Robert J. Kurman, Russell Vang — 2011
• Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinomaHaruhiko Nakayama, Sakae Okumura, Hiromitsu Daisaki — 2010
• Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assayMarileila Varella‐Garcia — 2006
• Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.Elisabetta Kuhn, Ren‐Chin Wu, Bin Guan — 2012

Cited by

• Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.Loredana Santo, Ka Tat Siu, Noopur Raje — 2015
• The Mutational Landscape of Endometrial CancerBo Hong, Matthieu Le Gallo, Daphne W. Bell — 2015
• Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.Aurelia Noske, Leigh A. Henricksen, Bonnie LaFleur — 2015
• The history and future of targeting cyclin-dependent kinases in cancer therapyUzma Asghar, Agnieszka K. Witkiewicz, Nicholas C. Turner — 2015
• Molecular Characterization of Undifferentiated Carcinoma Associated With Endometrioid CarcinomaElisabetta Kuhn, A. Ayhan, Asli Bahadirli-Talbott — 2014
• Novel Molecular Markers for Breast CancerKazushi Inoue, Elizabeth A. Fry — 2016
• Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.Robert Roskoski — 2016
• Immunohistochemical Profiling of Endometrial Serous CarcinomaWenqian Chen, Arjumand Husain, Gregg Nelson — 2016
• Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivoEmiliano Cocco, Salvatore Lopez, Jonathan Black — 2016
• CCNE1 Amplification and Centrosome Number Abnormality in Serous Tubal Intraepithelial Carcinoma- Further Evidence Supporting its Role as a Precursor of Ovarian High-Grade Serous CarcinomaElisabetta Kuhn, Tian‐Li Wang, Kai Doberstein — 2016
• Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.Justyna Kanska, Mae Zakhour, Barbie Taylor‐Harding — 2016
• Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Uterine Tumors.Lauren L. Ritterhouse, Brooke E. Howitt — 2016
• Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancerAurelia Noske, Simone Brandt, Nadejda Valtcheva — 2016
• CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosisA. Ayhan, Elisabetta Kuhn, Ren‐Chin Wu — 2017
• Pathology of Endometrial Carcinoma.Sigurd Lax — 2017
• Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancerBic-Na Song, Seon‐Kyu Kim, In‐Sun Chu — 2017
• Cell cycle regulation and anticancer drug discoveryBai Jingwen, Li Yao-Chen, Zhang Guo-jun — 2017
• Precision Molecular Pathology of Uterine CancerMichael T. Deavers, Donna Coffey — 2017
• Recent advances in CDK inhibitors for cancer therapy.Amy B. Heptinstall, IWS Adiyasa, Céline Cano — 2018
• HetRCNA: A Novel Method to Identify Recurrent Copy Number Alternations from Heterogeneous Tumor Samples Based on Matrix Decomposition FrameworkJianing Xi, Ao Li, Minghui Wang — 2020

Related papers

• Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization.Steffen Hauptmann, Carsten Denkert, Ines Koch — 2002
• Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis.Jie Hu, Vineesh Khanna, Matthew W. Jones — 2003
• Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.Annette Staebler, Kerstin Heselmeyer‐Haddad, Karen A. Bell — 2002
• Stage IA uterine serous carcinoma: a study of 13 cases.M. L. Carcangiu, Lee K. Tan, J.T. Chambers — 1997
• Diagnostic and molecular genetic pathology of serous borderline tumours of the ovaryJoachim Diebold, Gudrun Amann, Florian Seemüller — 2004
• Minor Serous and Clear Cell Components Adversely Affect Prognosis in ‘‘Mixed-Type’’ Endometrial Carcinomas: A Clinicopathologic Study of 36 Stage-I CasesM. Ruhul Quddus, Chih‐Wei Sung, Cunxian Zhang — 2010
• Patterns of Low-grade Serous Carcinoma With Emphasis on the Nonepithelial-lined Spaces Pattern of Invasion and the Disorganized Orphan PapillaeElvio G. Silva, Michael T. Deavers, Anaís Malpica — 2010
• Molecular pathogenesis of serous Fallopian tube and ovarian carcinomaMarlies E. Nowee — 2009
• Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation.Darren Wheeler, Karen A. Bell, Robert J. Kurman — 2000